Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · T. Rowe Price

T. Rowe Price Health Sciences Fund, Inc. T. Rowe Price Health Sciences Fund-I Class (THISX)

Ticker THISX · Since 2016-03-23 · · Holdings as of Jun 30, 2026

Expense ratio
0.68%$68/yr per $10k
5-yr return
+4.3%annualized
1-yr return
+17.9%as of Dec 2025
Net assets
$11.9Ball share classes
Holdings
279

Bottom line

Is THISX a good fund? The bottom line

THISX is the T. Rowe Price Health Sciences Fund-I Class share class of T. Rowe Price Health Sciences Fund, Inc., an actively managed health care sector mutual fund from T. Rowe Price.

Its expense ratio is 0.68% — about $68 a year on every $10,000 invested, cheaper than 70% of health care sector funds we track.

It returned +17.9% over one year, +4.3% a year over five years (as of Dec 31, 2025, per its prospectus).

With $11.9 billion in net assets and 279 holdings, its largest position is Eli Lilly & Co (14.3%) and the top 10 make up 47.6% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 80% top-holdings overlap).

What stands out

  • Broadly diversified (279 holdings)
  • Large and established ($11.9 billion)

Updated Nov 19, 2026

What THISX invests in

The fund seeks long-term capital appreciation.

In the Summary Prospectus, and Sections 1 and 2 of the Prospectus, the disclosure under Principal Investment Strategies is supplemented as follows: The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.

From the fund's prospectus (filed Jun 30, 2026).

THISX performance

Average annual total returns
1 yr5 yr10 yr
THISX+17.9%+4.3%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full THISX performance history →

What THISX costs

On a $10,000 investment, THISX's 0.68% expense ratio costs about $68 a year. The prospectus estimates $847 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full THISX fee table →

THISX top 10 holdings

#Holding% of fund
1Eli Lilly & Co14.28%
2Johnson & Johnson6.63%
3Unitedhealth Group Inc5.99%
4Abbvie Inc5.10%
5Merck & Co. Inc.4.01%
6Gilead Sciences Inc2.82%
7Thermo Fisher Scientific Inc2.52%
8Vertex Pharmaceuticals Inc2.28%
9Bristol-myers Squibb Co2.11%
10Abbott Laboratories1.89%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 47.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to THISX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%80% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%78% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%79% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%77% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%58% Compare
SchwabSWHFX Schwab Health Care Fund0.8%73% Compare

More funds like THISX →

THISX FAQ

What is the expense ratio of THISX?
THISX's expense ratio is 0.68%, which works out to about $68 a year for every $10,000 invested. The prospectus estimates total costs of $847 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is THISX a good investment?
It depends on your goals, but the data points to: broadly diversified (279 holdings); large and established ($11.9 billion). This is general information, not personalized advice.
What does THISX hold?
THISX's largest holdings are Eli Lilly & Co (14.3%), Johnson & Johnson (6.6%), Unitedhealth Group Inc (6.0%), Abbvie Inc (5.1%), Merck & Co. Inc. (4.0%). It holds 279 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is THISX's 5-year return?
THISX returned +4.3% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
What is a cheaper alternative to THISX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 80% with THISX and charges 0.08%.
Who manages THISX?
THISX is offered by T. Rowe Price through T. Rowe Price Health Sciences Fund, Inc..